Search

everythinglearnresearchcommunity

for

Search:↓

The user started a hair loss treatment in March 2025 using finasteride, minoxidil, omega-3, biotin, a DHT-blocking multivitamin, and a derma roller, and is satisfied with the progress after four months. The community is impressed with the results, noting significant hair regrowth and improvement.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

A 21-year-old male uses minoxidil, finasteride, and dutasteride for hair loss but still experiences progression with high DHT levels. Suggestions include increasing dosages, checking for deficiencies, considering a hair system, or consulting a specialist.

Oral minoxidil can cause severe side effects, including heart issues, even at low doses. Users suggest starting with a lower dose or using topical treatments to minimize risks.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

The conversation discusses a user's positive experience with a hair loss treatment routine involving dutasteride, oral minoxidil, and Nourkrin Man, with no side effects reported. Other users share their experiences with similar treatments, discussing side effects like heart palpitations and depression, and offer advice on obtaining prescriptions affordably.

The user experienced erectile dysfunction from oral finasteride and is considering alternatives like topical high-dose finasteride, RU58841, topical Latanoprost, and oral Minoxidil. Blood tests showed changes in testosterone and DHT levels, and the endocrinologist advised stopping finasteride.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Creatine is unlikely to worsen hair loss for those on finasteride, with no strong scientific evidence linking it to increased hair loss. Many users report no negative effects on hair while using creatine.

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.